Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib Maintenance in High-Risk Soft Tissue Sarcoma
NCT02207309Phase 2Terminated
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Jun 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib in soft tissue sarcoma (STS), sponsored by Ludwig Maximilian University of Munich. Started Jun 2015; status: terminated.
02
Drugs
pazopanib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02207309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207309.